期刊文献+

银杏酮酯磷脂复合物的制备与理化性质的研究 被引量:5

Preparation of Ginkgo biloba Extract 50-Phospholipid Complex and Study on Its Physicochemical Properties
下载PDF
导出
摘要 目的:制备银杏酮酯的磷脂复合物并优化制备工艺,对其进行理化性质的考察。方法:以黄酮醇苷与大豆磷脂的复合率为指标,进行单因素考察,并用正交试验优化制备工艺。对银杏酮酯磷脂复合物进行DSC和IR理化性质的鉴定,测定其在不同pH的溶液中的表观油水分配系数。结果:以四氢呋喃为反应溶剂,反应温度为30℃,反应物质的浓度为20 mg/mL,反应物质的重量比为1∶1时反应生成的复合物复合率达98%,并且银杏酮酯磷脂复合物明显改善了银杏酮酯在正辛醇中的溶解性能,在不同pH水-正辛醇系统中,银杏酮酯磷脂复合物的表观油水分配系数与银杏酮酯相比也有差异。结论:银杏酮酯磷脂复合物的理化性质相比银杏酮酯有较显著的改变。 Objective: To optimize the preparation technology of GBE 50-phospholipid complex and study its physicochemical properties.Methods: The preparation conditions for GBE 50-phospholipid complex were optimized by means of single factor study and orthogonal design,and taking the complexing rate of total flavonoids as assessmant criteria,the complex was analyzed by DSC,IR and determined apparent oil-water distribution coefficients in different pH aqueous solution.Results: The optimized preparation conditions for GBE 50-phospholipid complex were obtained as follows: the solvent was Tetrahydrofuran,the temperature was 30℃,the concentration of GBE 50 was 20 mg/mL,the ratio of GBE 50 to phospholipids was 1 to 1,and the complexing rate was 98%.The complex significantly improved GBE 50 on the solubility in octanol,also on the oil-water apparent partition coefficient.Conclusion: GBE 50-phospholipid complex is very different from GBE 50 on the physicochemical properties.
出处 《中药材》 CAS CSCD 北大核心 2010年第10期1624-1628,共5页 Journal of Chinese Medicinal Materials
关键词 银杏酮酯 磷脂复合物 黄酮醇苷 复合率 理化性质 Ginkgo biloba Extract 50(GBE 50) Phospholipid complex Flavonoides Complexing rate Physicochemical properties
  • 相关文献

参考文献6

二级参考文献33

  • 1杨鸿波,邱国福,梁淑彩,何建社,许健,胡先明.银杏磷脂复合物复合率的测定[J].分析测试学报,2005,24(1):106-108. 被引量:10
  • 2毛凤斐,南京药学院学报,1984年,15卷,1期,61页
  • 3Giacomelli S, Gallo D, Apollonio P, et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin[ J]. Life Sci ,2002,70(12): 1447.
  • 4Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients[J]. Transplantation ,2004, 77(2) :232.
  • 5Subira M, Martino R, Sureda A, et al. Safety and efficacy of lowdose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies[J]. Methods Find Exp Clin Pharmacol,2001,23(9): 505.
  • 6Knoppert DC, Salama HE, Lee DS. Eradication of severe neonatal systemic candidiasis with amphotericin B lipid complex [J]. Ann Pharmacother,2001, 35(9): 1032.
  • 7Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infectuions in immunosuppressed paediatric patients[ J]. Eur J Clin Microbiol Infect Dis ,2001,20(2) :77.
  • 8Laguna F, Videala S, Jimenez-Mejias ME, et al. Amphotericin Blipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study[ J] .Antimicrob Chemother ,2003, 52(3) :464.
  • 9Gabetta B, Bombardelli E, Pifferi G. Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions[P] .Eur Patent,209038, 1986-07-07.
  • 10吴建梅,陈大为,孙波,李三鸣,张汝华.天然活性成分磷脂复合物药学研究概述[J].中国药学杂志,1998,33(1):9-11. 被引量:47

共引文献84

同被引文献86

引证文献5

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部